HIV Scientific Papers
IV Push Administration of Ibalizumab: Pharmacokinetics, Safety, and Efficacy
2022
Edwin DeJesus, Gary Richmond, Mezgebe Berhe, Anthony Mills, Tanya Schreibman, Charlotte-Paige Rolle, Kuei-Ling Kuo, Mohammed Zogheib, Olivia G. Goss, R. Brandon Cash, YingAn Lai, Martin Markowitz, Pedro M. Mesquita
HIV-1 Non-Group M Phenotypic Susceptibility to Ibalizumab
2022
L. Poisson-Arnaud, Quentin le Hingrat, JC Plantier and E Alessandri-Gradt
Efficacy, pharmacokinetics, and safety over 48 weeks with ibalizumab-based therapy in treatment-experienced adults infected with HIV-1: a phase 2a study.
2021
J Acquir Immune Defic Syndr.
Gathe JC, Hardwicke RL, Garcia F, et al.
86(4):482-489.
Assessment of genotypic patterns associated with HIV-1 sensitivity to ibalizumab [abstract].
2020
Reviews in Antiviral Therapy & Infectious Diseases.
Jullien H, Leonard M, Cash RB, et al.
7:27. Proceedings of the European Meeting on HIV & Hepatitis 2020.
Assessment of genotypic patterns associated with HIV-1 sensitivity to ibalizumab.
2020
Jullien H, Leonard M, Cash RB, et al.
Poster #27 presented at: European Meeting on HIV & Hepatitis 2020; October 28-30 2020; virtual.